Call for Paper
Special Issue of the Journal of Nephrology and Renal Transplantation
Title: Resistance to recombinant human erythropoietin therapy in haemodialysis patients.
Anaemia is a common complication in haemodialysis patients, resulting in a significant mortality and morbidity in these patients. This anaemia is associated to a decreased bone marrow production of erythrocyte, due to the inability of the failing kidneys to secrete erythropoietin (EPO). The introduction of recombinant human EPO (rhEPO) therapy led to a significant reduction in anemia and improved patients’ quality of life. However, there is a marked variability in the sensitivity to rhEPO, with up to 10-fold variability in dose requirements to achieve correction of anemia. Approximately 5-10% of the patients show a marked resistance to rhEPO therapy.
This variability in the response to rhEPO therapy remains relatively unexplained. rhEPO resistance is associated with several condition. However exclusion of these factors does not eliminate the marked variability in the sensitivity to rhEPO therapy.
Resistance to rhEPO therapy is an important difficulty in the approach of some haemodialysis patients,
Submission Deadline: 30th April 2009
Deadline for initial reviews: 1st June 2009
First Notification: 15th June 2009
Camera Ready papers due: 15th July 2009
Final Notification of Acceptance/Rejection: 31th July 2009
All the papers should be full journal length versions and follow the guidelines set out by JNRT. All the papers will be peer-reviewed based on standard JNRT reviewing procedures.
Papers should be submitted through the JNRT online submission website as special issue papers. Please specify the title of this special issue in the “Comments for the Editor” section while submitting the paper.
Instituto de Ciências da Saúde
Universidade Católica Portuguesa
Campus da Asprela
Rua Dr. António Bernardino de Almeida
Phone: +351 225 580 001
Fax: +351 225 090 351